Functional organ preservation in patients with locoregionally advanced head and neck squamous cell carcinoma treated by platinum-based multidrug induction chemotherapy and concurrent chemoradiotherapy
Open Access
- 27 January 2011
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 22 (8) , 1894-1901
Abstract
Background: The objective of this study was to evaluate the feasibility, safety, and efficacy in terms of functional organ preservation of multidrug induction chemotherapy and concurrent chemoradiotherapy (IC–CCRT) protocol in patients with locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). Patients and methods: Patients with previously untreated, inoperable, histologically proven nonmetastatic stage III or IV HNSCC were eligible. Following one cycle of IC, two cycles of cisplatinum and 5-fluorouracil CCRT with conventional fractionated radiotherapy up to a dose of 66–70 Gy were administrated. Results: Between January 2000 and July 2007, a total of 139 patients were candidates to receive IC–CCRT for LA-HNSCC. Overall, 83% of the patients completed the treatment. Three-year overall survival estimate was 68% [95% confidence interval (CI) 57% to 79%]. Three-year progression-free survival (PFS) estimate was 62% (95% CI 50% to 74%). Three-year functional PFS was 57% (95% CI 44% to 69%). There were no cases of treatment-related deaths. The most frequent severe acute toxicity was pharyngeal mucositis. Conclusions: Cisplatinum-based multidrug IC–CCRT can result in functional organ preservation and curative treatment in most patients with LA-HNSCC. The toxicity profile and patients’ compliance to treatment confirmed the safety and tolerability of this approach.Keywords
This publication has 36 references indexed in Scilit:
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- Current concepts for the management of head and neck cancer: ChemotherapyOral Oncology, 2009
- Accelerated versus Conventional Radiotherapy with Concomitant Chemotherapy in Locally Advanced Head and Neck Carcinomas: Results of a Phase III Randomized TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck CancerNew England Journal of Medicine, 2007
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerNew England Journal of Medicine, 2007
- Single-Cycle Induction Chemotherapy Selects Patients With Advanced Laryngeal Cancer for Combined Chemoradiation: A New Treatment ParadigmJournal of Clinical Oncology, 2006
- Hyperfractionated Accelerated Chemoradiation With Concurrent Fluorouracil-Mitomycin Is More Effective Than Dose-Escalated Hyperfractionated Accelerated Radiation Therapy Alone in Locally Advanced Head and Neck Cancer: Final Results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 Prospective Randomized TrialJournal of Clinical Oncology, 2005
- Randomized Phase III Trial of Neoadjuvant Chemotherapy in Head and Neck Cancer: 10-Year Follow-UpJNCI: Journal of the National Cancer Institute, 2004
- Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal CancerNew England Journal of Medicine, 2003
- Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III TrialJNCI: Journal of the National Cancer Institute, 1996